SG10201913266UA - Materials and methods for delivering nucleic acids to cochlear and vestibular cells - Google Patents
Materials and methods for delivering nucleic acids to cochlear and vestibular cellsInfo
- Publication number
- SG10201913266UA SG10201913266UA SG10201913266UA SG10201913266UA SG10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA SG 10201913266U A SG10201913266U A SG 10201913266UA
- Authority
- SG
- Singapore
- Prior art keywords
- cochlear
- materials
- methods
- nucleic acids
- delivering nucleic
- Prior art date
Links
- 239000000463 material Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000001720 vestibular Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266462P | 2015-12-11 | 2015-12-11 | |
| US201562266477P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913266UA true SG10201913266UA (en) | 2020-02-27 |
Family
ID=59013436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913266UA SG10201913266UA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| SG11201804814YA SG11201804814YA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804814YA SG11201804814YA (en) | 2015-12-11 | 2016-12-12 | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11167042B2 (https=) |
| EP (2) | EP3386537B1 (https=) |
| JP (3) | JP6990182B2 (https=) |
| KR (1) | KR102794870B1 (https=) |
| CN (2) | CN109310745B (https=) |
| AU (1) | AU2016366846B2 (https=) |
| CA (1) | CA3007476A1 (https=) |
| ES (1) | ES2903000T3 (https=) |
| SG (2) | SG10201913266UA (https=) |
| WO (1) | WO2017100791A1 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10834922B2 (en) * | 2014-11-26 | 2020-11-17 | Microban Products Company | Surface disinfectant with residual biocidal property |
| SG10201913266UA (en) | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
| WO2018145111A1 (en) * | 2017-02-06 | 2018-08-09 | Children's Medical Center Corporation | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| JP2020509786A (ja) * | 2017-03-17 | 2020-04-02 | レスキュー ヒヤリング インコーポレイテッド | 聴覚損失の治療のための遺伝子治療構成物および方法 |
| US12391936B2 (en) | 2017-03-17 | 2025-08-19 | Rescue Hearing, Inc. | Gene therapy systems and related methods for treatment of hearing loss |
| KR102606810B1 (ko) | 2017-05-05 | 2023-11-27 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 오토펄린을 발현시키기 위한 조성물 및 방법 |
| US20210154326A1 (en) * | 2017-06-26 | 2021-05-27 | Arizona Board Of Regents On Behalf Of Arizona State University | CRISPR-Based Synthetic Gene Circuits as Next Generation Gene Therapy of Inner Ear |
| EP3661523A4 (en) * | 2017-08-03 | 2021-08-04 | University of Iowa Research Foundation | TREATMENT METHODS FOR GENETIC HEARING LOSS |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| DE102018100619A1 (de) | 2018-01-12 | 2019-07-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Gentherapeutische Behandlung von Schwerhörigkeit |
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| DE102018103924A1 (de) | 2018-02-21 | 2019-08-22 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Gentherapeutische Behandlung von Schwerhörigkeit |
| EP3762040A4 (en) * | 2018-03-05 | 2022-01-05 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS OF ADMINISTRATION OF NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS |
| BR112020019079A2 (pt) | 2018-03-23 | 2020-12-29 | Massachusetts Eye And Ear Infirmary | Abordagem de salto de éxon mediada por crispr/cas9 para síndrome de usher associada a ush2a |
| WO2019200016A1 (en) * | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CN112703016B (zh) * | 2018-04-27 | 2024-11-22 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| CA3100006A1 (en) * | 2018-05-11 | 2019-11-14 | Massachusetts Eye And Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
| US20210277417A1 (en) * | 2018-06-25 | 2021-09-09 | Akouos, Inc. | Methods of treating clrn1-associated hearing loss and/or vision loss |
| WO2020014625A1 (en) * | 2018-07-13 | 2020-01-16 | Akouos, Inc. | Methods of treating non-syndromic sensorineural hearing loss |
| US20210290727A1 (en) * | 2018-08-01 | 2021-09-23 | University Of Maryland, Baltimore | MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION |
| EP3856227A4 (en) * | 2018-09-27 | 2022-07-06 | Akouos, Inc. | METHODS OF TREATMENT OF AUDITORY NEUROPATHY SPECTRUM DISEASE |
| WO2020077295A1 (en) * | 2018-10-11 | 2020-04-16 | Decibel Therapeutics, Inc. | Aav1 vectors and uses thereof for treatment of otic indications |
| EP3880827A4 (en) * | 2018-11-07 | 2023-04-26 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR INDUCING DIFFERENTIATION OF A HAIR CELL |
| EP4063510A1 (en) * | 2018-11-07 | 2022-09-28 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| EP4295913A3 (en) | 2019-01-18 | 2024-03-06 | Institut Pasteur | Aav-mediated gene therapy restoring the otoferlin gene |
| CA3129422A1 (en) | 2019-02-08 | 2020-08-13 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP3921032A4 (en) * | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| US20220202957A1 (en) * | 2019-04-09 | 2022-06-30 | The Regents Of The University Of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
| CN110129368B (zh) * | 2019-04-22 | 2021-03-09 | 中国科学院脑科学与智能技术卓越创新中心 | 一种感染支持细胞和毛细胞的aav载体 |
| US11278013B2 (en) | 2019-04-26 | 2022-03-22 | Usher 2020 Foundation | Large animal model for developing therapeutic agents to treat impaired ophthalmic function in usher syndrome |
| EP3959324B1 (en) | 2019-04-26 | 2025-09-17 | President and Fellows of Harvard College | Aav vectors encoding mini-pcdh15 and uses thereof |
| WO2020223933A1 (zh) * | 2019-05-08 | 2020-11-12 | 中国科学院脑科学与智能技术卓越创新中心 | 高效感染支持细胞的aav突变体 |
| EP3999647A1 (en) * | 2019-07-18 | 2022-05-25 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
| CN110423778B (zh) * | 2019-07-26 | 2023-04-21 | 上海科技大学 | 一种逆行性重组2型腺相关病毒在感染螺旋神经元中的应用 |
| CA3153972A1 (en) | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
| WO2021067448A1 (en) | 2019-09-30 | 2021-04-08 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav) systems for treatment of genetic hearing loss |
| AU2020366531A1 (en) * | 2019-10-18 | 2022-05-26 | Research Institute At Nationwide Children's Hospital | Gene therapy targeting cochlear cells |
| KR20220130093A (ko) | 2019-10-30 | 2022-09-26 | 데시벨 테라퓨틱스, 인크. | 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법 |
| EP4055175A4 (en) | 2019-11-04 | 2023-11-29 | Decibel Therapeutics, Inc. | Cochlear inner hair cell promoters and uses thereof |
| TWI902721B (zh) * | 2019-11-04 | 2025-11-01 | 美商迪賽博治療公司 | 前庭支持細胞啟動子及其用途 |
| WO2021108512A1 (en) * | 2019-11-27 | 2021-06-03 | Icahn School Of Medicine At Mount Sinai | Gene therapy for the regeneration of auditory hair cells |
| US20230047254A1 (en) * | 2019-12-29 | 2023-02-16 | Gloriana Therapeutics | Mammalian Cells Secreting GDNF and Their Therapeutic Use |
| KR20220157944A (ko) | 2020-02-21 | 2022-11-29 | 아카우오스, 인크. | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 |
| CN115666658A (zh) | 2020-04-01 | 2023-01-31 | 佛罗里达州大学研究基金会 | 具有提高的治疗ush1b的安全性的双aav-myo7a载体 |
| WO2021222682A1 (en) * | 2020-04-30 | 2021-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Application of aav44.9 vector in gene therapy for the inner ear |
| IL298128A (en) * | 2020-05-13 | 2023-01-01 | Akouos Inc | Compositions and methods for treating slc26a4-associated hearing loss |
| WO2021231538A2 (en) * | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| WO2021231808A2 (en) * | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating gjb2-associated hearing loss |
| KR102326582B1 (ko) * | 2020-05-15 | 2021-11-16 | 사회복지법인 삼성생명공익재단 | 청각장애의 진단용 마커 및 그의 용도 |
| WO2022032151A1 (en) * | 2020-08-07 | 2022-02-10 | University Of Miami | Treatment of sensorineural deafness |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| EP4262882A1 (en) * | 2020-12-18 | 2023-10-25 | Institut Pasteur | Gene therapy for treating usher syndrome |
| CA3216712A1 (en) * | 2021-04-14 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Materials and methods for neurofibromin 2/merlin (nf2) gene therapy |
| AU2022271238A1 (en) * | 2021-05-04 | 2023-12-14 | Decibel Therapeutics, Inc. | Vestibular supporting cell promoters and uses thereof |
| CN113604469B (zh) * | 2021-08-11 | 2023-01-24 | 复旦大学附属眼耳鼻喉科医院 | 基于CRISPR/CasRx的基因编辑方法及其应用 |
| EP4409009A4 (en) * | 2021-09-30 | 2025-12-17 | Akouos Inc | Compositions for administering gene therapy and methods for treating hearing loss |
| US20250073354A1 (en) * | 2021-12-23 | 2025-03-06 | University Of Rochester | Compositions and methods for delivery of agents to inner ear |
| WO2023147383A1 (en) | 2022-01-25 | 2023-08-03 | Bridgebio Services Inc. | Gene therapy for genetic hearing loss |
| GB202214972D0 (en) * | 2022-10-11 | 2022-11-23 | Ucl Business Ltd | Products and methods for use in treating NDP-related diseases |
| WO2024151703A2 (en) * | 2023-01-12 | 2024-07-18 | Ohio State Innovation Foundation | Gene therapy for treating hearing loss disorders |
| CN121311586A (zh) * | 2023-05-12 | 2026-01-09 | 苏州星奥拓维生物技术有限公司 | 耳蜗內毛细胞特异性启动子及其应用 |
| CN121816425A (zh) | 2023-09-11 | 2026-04-07 | 学校法人顺天堂 | 能够感染内耳的aav变体 |
| WO2025085845A1 (en) * | 2023-10-19 | 2025-04-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gene therapy for hearing loss and vestibular disorders |
| US20250276095A1 (en) | 2024-03-04 | 2025-09-04 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy |
| WO2025226842A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Expression control by drg-expressed mirnas |
| WO2025226841A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Gene therapy approach for treating disorders associated with tnnt2 |
| WO2026011008A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Expression control by skeletal muscle-expressed mirnas |
| WO2026011009A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
| WO2026030242A1 (en) | 2024-07-29 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy |
| WO2026030244A1 (en) | 2024-07-30 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a |
| WO2026050402A1 (en) | 2024-08-29 | 2026-03-05 | Kate Therapeutics, Inc. | Liver de-targeted muscle tropic capsids |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037384B2 (en) | 1988-01-12 | 1995-12-26 | Cornell Res Foundation Inc | Method and apparatus for the treatment of complicated retinal detachments |
| US20040115621A1 (en) | 2000-02-18 | 2004-06-17 | Allen Rodrigo | Ancestral viruses and vaccines |
| US6692526B1 (en) | 2000-03-15 | 2004-02-17 | Michael E. Snyder | Ophthalmological surgery colorant and delivery system |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| EP1755400A2 (en) * | 2004-06-18 | 2007-02-28 | The University Of Montana | Aav mediated gene delivery to cochlear cells |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| US8388668B2 (en) | 2005-08-05 | 2013-03-05 | Gholam A. Peyman | Methods to regulate polarization of excitable cells |
| WO2011075838A1 (en) | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| US20150079110A1 (en) * | 2012-03-05 | 2015-03-19 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
| CN106232618A (zh) * | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| JP7103750B2 (ja) * | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| EP3258955A1 (en) * | 2015-02-20 | 2017-12-27 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
| SG10201913266UA (en) | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| EP3510161A4 (en) * | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
-
2016
- 2016-12-12 SG SG10201913266UA patent/SG10201913266UA/en unknown
- 2016-12-12 CN CN201680079432.3A patent/CN109310745B/zh active Active
- 2016-12-12 CN CN202211693839.9A patent/CN116236591B/zh active Active
- 2016-12-12 AU AU2016366846A patent/AU2016366846B2/en active Active
- 2016-12-12 WO PCT/US2016/066225 patent/WO2017100791A1/en not_active Ceased
- 2016-12-12 KR KR1020187019786A patent/KR102794870B1/ko active Active
- 2016-12-12 EP EP16874069.4A patent/EP3386537B1/en active Active
- 2016-12-12 CA CA3007476A patent/CA3007476A1/en active Pending
- 2016-12-12 SG SG11201804814YA patent/SG11201804814YA/en unknown
- 2016-12-12 ES ES16874069T patent/ES2903000T3/es active Active
- 2016-12-12 US US16/060,841 patent/US11167042B2/en active Active
- 2016-12-12 EP EP21202250.3A patent/EP3984550A1/en active Pending
- 2016-12-12 JP JP2018529927A patent/JP6990182B2/ja active Active
-
2021
- 2021-10-05 US US17/450,008 patent/US12102692B2/en active Active
- 2021-12-03 JP JP2021196596A patent/JP7309827B2/ja active Active
-
2023
- 2023-07-05 JP JP2023110371A patent/JP7745594B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180369414A1 (en) | 2018-12-27 |
| AU2016366846B2 (en) | 2022-03-17 |
| US11167042B2 (en) | 2021-11-09 |
| ES2903000T3 (es) | 2022-03-30 |
| EP3386537A1 (en) | 2018-10-17 |
| CN116236591B (zh) | 2026-02-27 |
| EP3386537A4 (en) | 2019-05-15 |
| JP2018536420A (ja) | 2018-12-13 |
| EP3386537B1 (en) | 2021-10-20 |
| KR102794870B1 (ko) | 2025-04-10 |
| CN109310745A (zh) | 2019-02-05 |
| CN116236591A (zh) | 2023-06-09 |
| US20220016262A1 (en) | 2022-01-20 |
| JP2023145460A (ja) | 2023-10-11 |
| US12102692B2 (en) | 2024-10-01 |
| JP2022046484A (ja) | 2022-03-23 |
| JP7309827B2 (ja) | 2023-07-18 |
| CN109310745B (zh) | 2022-12-06 |
| SG11201804814YA (en) | 2018-07-30 |
| WO2017100791A1 (en) | 2017-06-15 |
| JP6990182B2 (ja) | 2022-02-15 |
| AU2016366846A1 (en) | 2018-06-21 |
| JP7745594B2 (ja) | 2025-09-29 |
| CA3007476A1 (en) | 2017-06-15 |
| KR20180097631A (ko) | 2018-08-31 |
| EP3984550A1 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913266UA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| IL259321A (en) | Preparations and methods for increasing gene expression in frogs | |
| IL251774A0 (en) | Methods and compositions for dosing in adoptive cell therapy | |
| SG11201605906UA (en) | Muscle-specific nucleic acid regulatory elements and methods and use thereof | |
| SG11201606934SA (en) | Improved reprogramming methods and cell culture platforms | |
| EP3230445A4 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| SMT202300257T1 (it) | Potenziamento dell’effetto dei linfociti t ingegnerizzati con car per mezzo della vaccinazione con acido nucleico | |
| IL243672A0 (en) | Circulation and amplification of ligase-assisted nucleic acids | |
| PL3215166T3 (pl) | Zmiana ekspresji genów w limfocytach car-t i ich zastosowanie | |
| SG11201609916RA (en) | Culture method and cell mass | |
| HUE065634T2 (hu) | Negatív elektróda aktív anyag és eljárás annak elõállítására | |
| GB2534873B (en) | Improvements in and relating to horseshoes | |
| SG11201705853VA (en) | Cell culture device and cell culture method | |
| IL258005A (en) | Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2 | |
| ZA201703443B (en) | Oral rehydration composition and methods thereof | |
| GB201410270D0 (en) | Cell delivery system and method | |
| LT3586821T (lt) | Kamienines ląsteles stimuliuojančios kompozicijos ir būdai | |
| IL246525A0 (en) | Pomegranate cell culture and methods for its preparation and use | |
| GB201522223D0 (en) | Therapeutic T cells | |
| SG11201702897WA (en) | Cell culture bag and cell culture method | |
| LT3194602T (lt) | Junginiai ir būdai, skirti virusinių genų pernešimui į žmogaus hematopoetines ląsteles | |
| EP3126500A4 (en) | Dna aptamers specific to cd200r1 and their therapeutic uses | |
| EP3258978A4 (en) | Methods and products for delivering cells | |
| EP3241848A4 (en) | Construction method for recombinant vaccine having anti-cervical cancer cell activity and application thereof | |
| TWI563085B (en) | Dendritic cell tumor vaccine and preparation method thereof |